The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid. Bullous pemphigoid ...
Credit: The Washington Post via Getty Images. Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin ...
Smoking may cause the damage that researchers associate with this type of emphysema. Bullous emphysema is a condition in which damage to the walls of the alveoli causes large pockets of air called ...
Quickly spreading erythema, ecchymosis with vesicles enlarging to purple bullae, should immediately alert the nurse to NF. Inside these purple bullae is a foul smelling, thin, watery fluid known ...
Exceptional Family Living in a Prime Kelso Location! Welcome to 16 Bulla Place, Kelso, a beautifully designed three-bedroom, two-bathroom home built in 2018, offering modern living with thoughtful ...
The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).
Dupilumab has been accepted for priority review by the US Food and Drug Administration (FDA) for the treatment of bullous pemphigoid (BP) in adults, according to a press release from the ...